NCT07264010 2025-12-04
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
Clinical Trials
8 trialsNCT05623267 2023-08-07
SURPASS
Sun Yat-sen University
Phase 2/3 Recruiting
NCT03093207 2020-11-17
Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis
Universidade Estadual Paulista Júlio de Mesquita Filho
Phase 2/3 Completed
NCT02870777 2020-03-04
MRD-directed Therapy for Low-risk and Intermediate-risk AML.
Nanfang Hospital, Southern Medical University
Phase 2/3 Completed
NCT02673008 2020-02-25
MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Completed
NCT03662087 2018-09-07
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03624530 2018-08-10
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT00795756 2014-10-22
Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia
Northern Italy Leukemia Group
Phase 2/3 Completed